Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Pichon

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid CarcinomaCharlotte Domblides, Karen Leroy, Isabelle Monnet, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
Lancet (London, England)|August 12, 2011
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialElisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
The Lancet. Oncology|December 17, 2021
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trialCecile Le Pechoux, Nicolas Pourel, Fabrice Barlesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 TrialFabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
The Lancet. Oncology|August 14, 2022
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trialVirginie Westeel, Pascal Foucher, Arnaud Scherpereel, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid CarcinomaCharlotte Domblides, Karen Leroy, Isabelle Monnet, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
Lancet (London, England)|August 12, 2011
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialElisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
The Lancet. Oncology|December 17, 2021
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trialCecile Le Pechoux, Nicolas Pourel, Fabrice Barlesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 TrialFabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
The Lancet. Oncology|August 14, 2022
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trialVirginie Westeel, Pascal Foucher, Arnaud Scherpereel, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Pageof 4